Form 4: Whitehawk Therapeutics Executive Stock Transactions

Scott M. Giacobello, Chief Financial Officer of Whitehawk Therapeutics, Inc., reported significant stock transactions including the acquisition of restricted stock units and stock options.

Summary

• Scott M. Giacobello, Chief Financial Officer of Whitehawk Therapeutics, Inc., reported transactions related to his beneficial ownership of company stock.
• On April 1, 2026, Mr. Giacobello acquired 473,902 Restricted Stock Units (RSUs).
• These RSUs are subject to vesting conditions, with 100% vesting on the one-year anniversary of the Vesting Commencement Date of April 1, 2025, provided he remains a Service Provider.
• Additionally, on April 1, 2026, Mr. Giacobello acquired a stock option to purchase 300,677 shares of common stock at an exercise price of $3.54.
• The stock option vests over four years, with 25% vesting on the one-year anniversary of the Vesting Commencement Date (April 1, 2026), and the remainder vesting monthly thereafter.
• Following these transactions, Mr. Giacobello beneficially owns 502,002 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider stock transactions without providing new financial or strategic information about the company's performance.

Positives

• The acquisition of RSUs and stock options by the CFO indicates a continued commitment and alignment with the company's performance.
• The vesting schedules for both RSUs and stock options are designed to incentivize long-term service and performance.
• The CFO's direct beneficial ownership of a significant number of shares (502,002) suggests a substantial personal investment in the company's success.

Negatives

• The filing details the acquisition of securities, but does not provide information on the company's financial performance or operational status, which could be considered a negative for investors seeking broader insights.
• The exercise price of the stock option ($3.54) implies a certain valuation expectation, but the current market price is not provided for comparison.

Risks

• The vesting of RSUs and stock options is contingent upon Mr. Giacobello continuing to be a Service Provider, meaning any departure before vesting would result in forfeiture of these awards.
• The value of the acquired RSUs and stock options is directly tied to the future performance and stock price of Whitehawk Therapeutics, Inc., which carries inherent market risk.

Future Outlook

The future outlook for the acquired RSUs and stock options is dependent on the continued service of the reporting person and the company's stock performance. The vesting schedules indicate a long-term perspective for these awards.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider stock transactions. The details of RSUs and stock options acquisition by a CFO are common in the biotechnology and pharmaceutical sectors, reflecting incentive structures tied to long-term growth and value creation.

Stakeholder Impact

• Shareholders: The transactions indicate continued executive commitment, which can be viewed positively, but do not directly impact share price without further company performance data.
• Employees: The vesting schedules for RSUs and options are standard executive compensation tools, aligning management with long-term company goals.
• Management: The CFO is increasing their direct beneficial ownership and potential future stake in the company through these equity awards.

Next Steps

• Vesting of RSUs on April 1, 2026 (one year after Vesting Commencement Date of April 1, 2025).
• Continued vesting of stock options on a monthly basis after April 1, 2026, over a four-year period.
• Continued service as a Service Provider to ensure vesting of awards.

Key Dates

Keywords

Form 4, SEC Filing, Stock Transaction, Restricted Stock Units, Stock Options, Beneficial Ownership, Whitehawk Therapeutics, Scott M. Giacobello, CFO, Equity Incentive Plan, Vesting Schedule